BEUDAMED
    FDA Adverse Event Injury Summary report: N

    VENT RES TR SAL-RIC ST BA

    MDR report key: 17894575 · Received October 9, 2023

    Report

    Report Number
    3013886523-2023-00346
    Event Type
    Injury
    Date Received
    October 9, 2023
    Date of Event
    July 21, 2021
    Report Date
    October 26, 2023
    Manufacturer
    INTEGRA LIFESCIENCES MANSFIELD
    Product Code
    JXG
    UDI-DI
    10381780517795
    PMA / PMN Number
    K102961
    Report Source
    Manufacturer report
    Reporter Occupation
    OTHER
    Health Professional
    N

    Narratives

    Additional Manufacturer Narrative · 0

    THE RICKHAM RESERVOIR VALVE (ID 821625) WAS NOT RETURNED FOR EVALUATION; THEREFORE, AN EVALUATION OF THE DEVICE COULD NOT BE PERFORMED. LOT NUMBER INFORMATION HAS BEEN PROVIDED; THEREFORE, DEVICE HISTORY RECORD (DHR) WAS REVIEWED, AND NO ANOMALIES WERE FOUND. THE ROOT CAUSE(S) OF THE REPORTED ISSUE COULD NOT BE DETERMINED HOWEVER, A POSSIBLE ROOT CAUSE FOR THE ISSUE REPORTED BY THE CUSTOMER, COULD BE DUE USER¿S ERROR, AS NOTED IN THE IFU ¿TO INHIBIT CORING OF THE RESERVOIR CAP, A HUBER TM POINT NEEDLE (24- OR 26- GAUGE) SHOULD BE USED TO PENETRATE THE DOME. IF ADDITIONAL RELEVANT INFORMATION BECOMES AVAILABLE IN THE FUTURE, THIS COMPLAINT WILL BE REOPENED, AND THE RESPECTIVE EVALUATION PERFORMED. TRENDS WILL BE MONITORED FOR THIS AND SIMILAR ISSUES. AT PRESENT, WE CONSIDER THIS COMPLAINT TO BE CLOSED.

    Additional Manufacturer Narrative · 0

    AN INVESTIGATION HAS BEEN INITIATED BASED ON THE REPORTED INFORMATION. UPON COMPLETION OF THE INVESTIGATION, A FOLLOW-UP REPORT WILL BE SUBMITTED.

    Description of Event or Problem · 0

    N/A.

    Description of Event or Problem · 0

    MEDWATCH: (B)(4). STUDY: THIS CASE IS A REPORT REFERRING TO A 7 YEARS-OLD MALE PATIENT. AN INVESTIGATOR REPORTED THIS CASE FROM THE BIOMARIN SPONSORED STUDY (CERLIPONASE ALFA OBSERVATIONAL STUDY). "THE SUBJECT'S PAST MEDICAL HISTORY INCLUDED DRUG DELIVERY DEVICE PLACEMENT. THE SUBJECT'S CONCURRENT CONDITIONS INCLUDED: SEIZURE, EPILEPSY, DEVELOPMENTAL DELAY, RETINAL DEGENERATION, NAUSEA, AND NEURONAL CEROID LIPOFUSCINOSIS. NO ALLERGIES WERE REPORTED. CONCOMITANT MEDICATION INCLUDED: CLOBAZAM, CLONAZEPAM, DIAZEPAM, ONDANSETRON HYDROCHLORIDE, LIDOCAINE-PRILOCAINE, AND CLONIDINE HYDROCHLORIDE. ON AN UNREPORTED DATE, THE SUBJECT UNDERWENT IMPLANTATION OF AN INTRACEREBRAL VENTRICULOSTOMY (ICV) SET (CODMAN & SHURTLEFF SALMON-RICKHAM; MODEL 82-1625) LOT NUMBER 4706837 (CATALOG NUMBER, SERIAL NUMBER, AND UDI NUMBERS NOT REPORTED)." "ON (B)(6) 2018, THE SUBJECT INITIATED TREATMENT WITH BRINEURA (300 MILLIGRAM, QOW, ICV). THE LOT NUMBER FOR BRINEURA WAS UNKNOWN. THE MOST RECENT DOSE WAS ADMINISTERED ON (B)(6) 2021." "ON (B)(6) 2021 AT 08:00, THE SUBJECT WAS HOSPITALIZED TO UNDERGO A GRADE 1 DEVICE REPLACEMENT DUE TO PORT DETERIORATION AND END OF LIFE USE OF THE DEVICE (DEVICE END OF SERVICE). IT WAS NOTED THAT THE SUBJECT'S ICV PORT HAD BEEN ACCESSED 90 TIMES. NO LABORATORY OR DIAGNOSTIC TESTS WERE REPORTED. NO ADDITIONAL TREATMENT FOR THE EVENT WAS REPORTED. NO ACTION WAS TAKEN WITH BRINEURA DUE TO THE EVENT. THE SUBJECT WAS REQUIRED TO STAY OVERNIGHT IN THE HOSPITAL FOR OBSERVATION. THE SUBJECT WAS DISCHARGED ON (B)(6) 2021 WITH NO COMPLICATIONS." "THE OUTCOME OF THE EVENT WAS REPORTED AS RECOVERED/RESOLVED ON (B)(6) 2021." "THE INVESTIGATOR ASSESSED THE EVENT OF DEVICE END OF SERVICE AS NOT RELATED TO TREATMENT WITH BRINEURA. THE INVESTIGATOR ASSESSED THE EVENT OF DEVICE END OF SERVICE AS RELATED TO THE SUBJECT'S ICV DEVICE. OTHER ETIOLOGICAL FACTORS INCLUDED END OF LIFE USE RESERVOIR REPLACEMENT. ADDITIONAL INFORMATION HAS BEEN REQUESTED AND, IF RECEIVED, THE REPORT WILL BE UPDATED." ADDITIONAL INFORMATION RECEIVED ON 20-SEP-2021: "THE ICV PORT WAS IMPLANTED ON (B)(6) 2018. NO FURTHER INFORMATION WAS AVAILABLE." ADDITIONAL INFORMATION RECEIVED ON 07-SEP-2023: "THE SUBJECT'S ADDITIONAL CONCURRENT CONDITIONS INCLUDED LANGUAGE DISORDER, MALNUTRITION, PAIN AND ANXIETY. THE SUBJECT'S ADDITIONAL CONCOMITANT MEDICATIONS INCLUDED PARACETAMOL, IBUPROFEN, FOLIC ACID/RETINOL/THIAMINE HYDROCHLORIDE/ERGOCALCIFEROL/ASCORBIC ACID/PYRIDOXINE HYDROCHLORIDE/CYANOCOBALAMIN/NICOTINAMIDE/TOCOPHERYL ACETATE/RIBOFLAVIN/FLUORINE, PYRIDOXINE HYDROCHLORIDE,RETINOL ACETATE AND LEVETIRACETAM. THE SUBJECT'S PREMEDICATION INCLUDED DIAZEPAM, ONDANSETRON HYDROCHLORIDE, LIDOCAINE/PRILOCAINE, PARACETAMOL, IBUPROFEN, FOLIC ACID/RETINOL/THIAMINE HYDROCHLORIDE/ERGOCALCIFEROL/ASCORBIC ACID/PYRIDOXINE HYDROCHLORIDE/CYANOCOBALAMIN/NICOTINAMIDE/TOCOPHERYL ACETATE/RIBOFLAVIN/FLUORINE, PYRIDOXINE HYDROCHLORIDE, CLONIDINEHYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE/PRILOCAINE HYDROCHLORIDE, RETINOL ACETATE AND LEVETIRACETAM." "THE SEVERITY OF THE EVENT WAS UPDATED BY THE INVESTIGATOR FROM GRADE 1 TO GRADE 3." CASE COMMENT: "ICV DEVICE WAS PROPHYLACTICALLY REPLACED DUE END OF LIFE CYCLE OF DEVICE. IT IS USUALLY DUE TO MATERIAL DEGRADATION OF DEVICE BECAUSE OF LONG PERIODS OF USE. THE CAUSALITY OF THE EVENT IS ASSESSED AS NOT RELATED TO BRINEURA."

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1711174 VENT RES TR SAL-RIC ST BA RESERVOIRS JXG INTEGRA LIFESCIENCES MANSFIELD 4706837 10381780517795

    Patients

    Seq Age Sex Outcome Treatment
    1 7 YR Male ACETAMINOPHEN (PARACETAMOL).| BRINEURA.| CLOBAZAM (CLOBAZAM).| CLONAZEPAM (CLONAZEPAM).| CLONIDINE (CLONIDINE HYDROCHLORIDE).| DIAZEPAM (DIAZEPAM).| EMLA (LIDOCAINE, PRILOCAINE).| IBUPROFEN (IBUPROFEN).| KEPPRA (LEVETIRACETAM).| LIDOCAINE PRILOCAINE BIOGARAN.| MULTIVITAMINS WITH FLUORIDE.| ONDANSETRON (ONDANSETRON HYDROCHLORIDE).| PYRIDOXINE HYDROCHLORIDE.| VITAMIN A (RETINOL ACETATE).